期刊文献+
任意字段
题名或关键词
题名
关键词
文摘
作者
第一作者
机构
刊名
分类号
参考文献
作者简介
基金资助
栏目信息

肿瘤的节拍化疗 被引量：4

Metronomic chemotherapy in human cancers
原文传递
导出
摘要 节拍化疗指以肿瘤内增殖的血管内皮细胞为靶点，通过持续应用低毒性剂量的药物而抑制肿瘤血管生成的一种化疗模式。节拍化疗在头颈部肿瘤、乳腺癌、消化道肿瘤、卵巢癌和前列腺癌中的成功应用显示了其潜在价值。节拍化疗的作用机制除抗肿瘤血管生成外，还包括刺激免疫和直接抗肿瘤效应，其与其他治疗模式的联合应用尚待深入探索。 Metronomic chemotherapy involves antiangiogenic processes that help host to fight against cancer by using continuous low dose drugs.Metronomic chemotherapy can be an effective treatment option for patients with head and neck carcinoma,breast cancer,gastrointestinal cancer,ovarian and prostate cancer. Metronomic chemotherapy also involves multiple mechanisms that include antiangiogenesis,immune stimulation and direct tumor cell targeting effects.We need to carefully evaluate the clinical effects of combination chemo-therapies that incorporate the other treatment schedules.
作者 张百红 岳红云
机构地区 兰州军区总医院肿瘤科 兰州军区总医院眼科
出处 《国际肿瘤学杂志》 CAS 2016年第7期523-525,共3页 Journal of International Oncology
基金 甘肃省自然科学基金（1308RJZA181）
关键词 肿瘤 药物疗法 血管生成抑制剂 Neoplasms Drug therapy Angiogenetic inhibitors
分类号 R730.53 [医药卫生—肿瘤]
  • 相关文献

参考文献22

  • 1Patil VM, Noronha V, Joshi A, et al. A prospective randomized phase H study comparing metronomic chemotherapy with chemothera- py (single agent cisplatin), in patients with metastatic, relapsed or inoperable squamous cell carcinoma of head and neck [ J ]. Oral Oncol, 2015, 51 ( 3 ) : 279-286.
  • 2Masuda N, Higaki K, Takano T, et al. A phase I1 study of metro- nomic paelitaxel/cyclophosphamide/capecitabine followed by 5-flu- orouracil/epirubicin/cyclophosphamide as preoperative chemotherapy for triple-negative or low hormone receptor expressing/HER2-negative primary breast cancer[ J]. Cancer Chemother Pharmacol, 2014, 74 (2) : 229-238.
  • 3Ferrandina G, Corrado G, Mascilini F, et al. Metronomic oral cyclo- phosphamide (MOC) in the salvage therapy of heavily treated recur- rent ovarian cancer patients : a retrospective, muhicenter study [ J ]. BMC Cancer, 2014, 14: 947.
  • 4Barroso-Sousa R, Da Fonseca LG, Souza KT, et al. Metronomic oral cyclophosphamide plus prednisone in docetaxel-pretreated patients with metastatic castration-resistant prostate cancer [ J ]. Med Oncol, 2015, 32(1) : 443.
  • 5Derosa L, Galli L, Orlandi P, et al. Docetaxel plus oral metronomic cyclophosphamide : a phase ]I study with pharmacodynamic and phar- macogenetic analyses in castration-resistant prostate cancer patients [J]. Cancer, 2014, 120(24) : 3923-3931.
  • 6Miger J, Holmqvist A, Sun XF, et al. Low-dose eapecitabine ( Xelo- da) for treatment for gastrointestinal cancer[ J]. Med Oncol, 2014, 31 (3) : 870.
  • 7Alici S, Buyukberber S, Alkis N, et al. Low-dose docetaxel/cispla- tin-leucovorin and 46 hour infusional fluorouracil in metastatic gastric carcinoma[ J]. Asian Pac J Cancer Prey, 2013, 14( 1 ) : 423-427.
  • 8Brandi G, De Rosa F, Agostini V, et al. Metronomic capecitabine in advanced hepatocellular carcinoma patients: a phase 11 study [ J ]. Oncologist, 2013, 18 (12) : 1256-1257.
  • 9Romiti A, Onesti CE, Roberto M, et al. Continuous, low-dose capecitabine for patients with recurrent colorectal cancer [ J ]. Med Oncol, 2015, 32(3): 54.
  • 10Le DT, Jaffee EM. Regulatory T-cell modulation using cyclophos- phamide in vaccine approaches : a current perspective [ J ]. Cancer Res, 2012, 72 (14) : 3439-3444.

二级参考文献29

  • 1Schiller JH.Comparison of four chemotherapy regimens for advanced non small-cell lung cancer[J].N Eng J Med,2002,346:92-98.
  • 2Leaf C.Why we are losing the war on cancer (and how to win it)[J].Fortune,2004,149:77-97.
  • 3Hanaban D,Bergers G,Bergsland E.Less is more,regularly:Metronomic dosing of cytotoxic drugs can target tumor angiogenesis in mice[J].J Clin Invest,2000,105(8):1045-1047.
  • 4Stempak D,Gammon J,Hahon J,et al.A pilot pharmacokinetic and antiangiogenic biomarker study of celecoxib and low-dose metronomic vinblastine or cyclophosphamide in pediatric recurrent solid tumors[J].J Pediatr Hematol Oncol,2006,28(11):720-728.
  • 5Havrilesky LJ,Alvarez AA,Sayer RA,et al.Weekly low-dose carboplatin and paclitaxel in the treatment of recurrent ovarian and peritoneal cancer[J].Gynecol Oncol,2003,88:51-57.
  • 6Sung CC,Chang PY,Chen MF,et al.Successful metronomic low-dose cyclophosphamide therapy in an older patient with advanced mucosa-associated lymphoid tissue lymphoma[J].Ann Hematol,2009,88:1257-1259.
  • 7Buckstein R,Kerbel RS,Shaked Y,et al.High-dose celecoxib and metronomic"low-dose"cyclophosphamide is an effective and safe therapy in patients with relapsed and refractory aggressive histology non-hodgkin's lymphoma[J].Clin Cancer Res,2006,12(17):5190-5198.
  • 8De Weerdt O,Van de Donk NW,Velh G,et al.Continuous low-dose cyclophosphamide-prednisone is effective and well tolerated in patients with advanced multiple myeloma[J].Neth J Med,2001,59(2):50-56.
  • 9Trieu Y,Trudel S,Pond GR,et al.Weekly cyclophosphamide and alternate-day prednisone:An effective,convenient,and well-tolerated oral treatment for relapsed multiple myeloma after autologous stem cell transplantation[J].Mayo Clin Proe,2005,80(12):1578-1582.
  • 10Suvannasankha A,Fausel C,Juliar BE,et al.Final report of toxicity and efficacy of a phase II study of oral cyclophosphamide,thalidomide,and prednisone for patients with relapsed or refractory multiple myeloma:A hoosier oncology group trial,HEM01-21[J].Oncologist,2007,12(1):99-106.

共引文献2

同被引文献23

引证文献4

二级引证文献4

国际肿瘤学杂志
2016年 第7期

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部